INVESTOR NOTICE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages BELLUS Health Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline - BLU Biotech Investing
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against BELLUS Health Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Biotech Investing
Lowey Dannenberg, P.C. Announces Filing of Securities Class Action Lawsuit Against Bellus Health Inc. on Behalf of Investors Who Acquired Shares from September 19, 2019 to July 5, 2020 and Encourages Investors to Inquire About the Lead Plaintiff Position Before the May 17, 2021 Lead Plaintiff Deadline Biotech Investing
Merck Announces Filing of Form 10 Registration Statement in Connection with Planned Spinoff of Organon & Co. Pharmaceutical Investing
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of BELLUS Health Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 17, 2021 - BLU Biotech Investing
SHAREHOLDER ALERT: Barr Law Group Investigating VNDA, VLDR, RIDE, and ABT; Shareholders are Encouraged to Contact the Firm Medical Device Investing
Solarvest Bioenergy Inc. Announces Non-Brokered Private Placement to Existing Shareholders and other Investors Biotech Investing
SHAREHOLDER ACTION ALERT: The Schall Law Firm Files Class Action Suit Against BELLUS Health Inc. Biotech Investing
BLU Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies BELLUS Health Inc. Investors of Class Action and Encourages Shareholders to Contact the Firm Biotech Investing
BLU BREAKING NEWS: ROSEN, A TOP RANKED LAW FIRM, Encourages BELLUS Health Inc. Investors to Secure Counsel Before Important Deadline - BLU Biotech Investing
AbbVie Announces Extension of Review for Supplemental New Drug Application of Upadacitinib for the Treatment of Adults with Active Psoriatic Arthritis Biotech Investing
European Commission Approves Expanded Indication for Merck's KEYTRUDA® in Adult and Pediatric Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Pharmaceutical Investing
